NEW YORK (GenomeWeb News) – XDx today announced a deal with Laboratory Corporation of America to develop and commercialize a diagnostic test for systemic lupus erythematosus (SLE).

The two firms will work together in the discovery phase while LabCorp will develop and commercialize a test to predict flares of lupus. The collaboration pairs XDx's autoimmune diagnostics research and discovery expertise as well as SLE blood sample database with LabCorp's diagnostic development and commercialization resources, they said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.